Nanophoria Bioscience
CONTACT
  • About us
    • About NanoPhoria
    • Team
    • Investors
  • Therapeutic focus
  • Our Platform
    • Drug Delivery Platform
    • Pipeline
    • Background Science
  • Clinical Programs
    • NP-MP1
  • News
    • Press releases

Month: May 2022

NanoPhoria receives a 3.5M€ seed grant from Sofinnova Partners a leading European life sciences venture capital firm based in Paris, London and Milan

Posted on 22 May 202210 February 2026 by Ed Gover
Posted in Press Release

NanoPhoria has been granted an exclusive patent licence for a drug delivery platform based on inorganic nanoparticles. This acquisition will aid in the launch new products capable of optimizing the results of therapies and reducing side effects for patients

Posted on 16 May 202210 February 2026 by Ed Gover
Posted in Press Release

Recent Posts

  • Test in the media
  • NanoPhoria Awarded Second-Place Prize in INNLIFES’ “I Protagonisti Dell’innovazione 2026” Contest
  • NanoPhoria Announces Second Close of its Series A Round, Now with Participation from European Innovation Council Fund 
  • NanoPhoria Named Startup of the Year by StartupItalia
  • NanoPhoria Bioscience secures €83.5 Million Series A to Advance Breakthrough Heart Failure Therapy and Expand Portfolio for Novel Nano-in-Micro Delivery Platform

Recent Comments

No comments to show.

Archives

  • July 2026
  • May 2026
  • January 2026
  • December 2025
  • October 2025
  • February 2025
  • January 2024
  • November 2022
  • June 2022
  • May 2022

Categories

  • In the Media
  • Press Release
Connect with us
Learn more about our company and the science behind our revolutionary technology platform
Get in touch
Terms of use
Privacy Policy
Cookies

© NanoPhoria S.r.l. All rights reserved.
VAT number: 12246020965